Jason Coloma Sells 34,501 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Posted by Stanley Muller on Sep 5th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at approximately $477,189.79. This represents a 65.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 1.3%

NASDAQ MAZE opened at $26.21 on Friday. The business’s 50-day moving average price is $28.69 and its two-hundred day moving average price is $31.17. Maze Therapeutics, Inc. has a 12 month low of $14.27 and a 12 month high of $53.65. The firm has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Trading of Maze Therapeutics

Large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Maze Therapeutics during the first quarter worth $57,000. Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics in the 1st quarter valued at about $145,000. Rhumbline Advisers acquired a new stake in Maze Therapeutics in the first quarter valued at approximately $80,000. Geode Capital Management LLC lifted its holdings in shares of Maze Therapeutics by 8.8% in the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after purchasing an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on MAZE shares. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $66.00.

Check Out Our Latest Report on MAZE

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.